Crossmark

Pharmacokinetics of liposomal curcumin (Lipocurc™) infusion: effect of co-medication in cancer patients and comparison with healthy individuals

Crossref DOI link: https://doi.org/10.1007/s00280-018-3730-5

Published Online: 2018-11-14

Published Print: 2019-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bolger, Gordon T.

Licollari, Albert

Tan, Amin

Greil, Richard

Vcelar, Brigitta

Greil-Ressler, Sigrun

Weiss, Lukas

Schönlieb, Charlotte

Magnes, Teresa

Radl, Bianca

Majeed, Muhammed

Sordillo, Peter P.
License Information

Text and Data Mining valid from 2018-11-14
More Information

Article History

Received: 17 August 2018

Accepted: 9 November 2018

First Online: 14 November 2018

Compliance with ethical standards

:

: PPS is vice president and chief scientific officer at SignPath Pharma Inc. No potential conflict of interest was disclosed by RG, BV, SGR, LW, CS, TM, BR, MM, GB, AL and AT. Cancer patients enrolled in this study provided written informed consent.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.